There are 805 resources available
129MO - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive (HER2+) advanced gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric06 (DG-06) final analysis
Presenter: Zhi Peng
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
403O - Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
Presenter: Wen Feng Fang
Session: Proffered Paper session: Head and neck cancers
Resources:
Abstract
269O - Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39
Presenter: Eiji Kikuchi
Session: Proffered Paper session: Genitourinary tumours
Resources:
Abstract
130MO - EDGE-Gastric Arm A1: Phase II study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer
Presenter: Sun Young Rha
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
404O - A phase III prospective randomised trial of two- weekly TPF(Taxane/Platinum/5FU) vs three weekly TPF as induction chemotherapy in locally advanced squamous cell carcinoma of head and neck: A preliminary analysis
Presenter: Animesh Gupta
Session: Proffered Paper session: Head and neck cancers
Resources:
Abstract
270O - Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone in Asian patients with previously untreated unresectable or metastatic urothelial carcinoma (u/mUC) from CheckMate 901
Presenter: Yoshihiko Tomita
Session: Proffered Paper session: Genitourinary tumours
Resources:
Abstract
131MO - Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
Presenter: Ken Kato
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
405O - Accuracy of plasma Epstein-Barr virus (EBV) DNA for disease surveillance in endemic nasopharyngeal carcinoma (NPC): Analysis of a real-world database (RWD)
Presenter: Melvin Lee Kiang Chua
Session: Proffered Paper session: Head and neck cancers
Resources:
Abstract
271O - Interim analysis (IA) of SPADE: A prospective, real-world study of avelumab first-line maintenance (1LM) treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Asia-Pacific (APAC) region
Presenter: Jungmin Jo
Session: Proffered Paper session: Genitourinary tumours
Resources:
Abstract
LBA9 - TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis
Presenter: Petros Grivas
Session: Proffered Paper session: Genitourinary tumours
Resources:
Abstract